Publication | Closed Access

LBA80 Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study

Rationale-305 StudyEsophageal CancerGastrointestinal OncologyMedicineGastroenterologyPathologySurgeryGastrointestinal PathologyAdvanced GastricOncologyRadiation OncologyLba80 TislelizumabCancer Research